Founded in 2022
Shanghai Saierxin Biomedical Technology focuses on the development of multimodal Treg cell therapies for the treatment of neurodegenerative diseases, autoimmune diseases, and metabolic diseases. There are many unmet medical needs in the above medical fields, which are lack or need of effective medications. After years of exploratory research, we have found that Treg cells can effectively inhibit the proliferation and function of pro-inflammatory cells in autoimmune diseases through multiple pathways. Based on its mechanism of action and our best knowledge and understanding, we expect to achieve significant therapeutic effects in the above disease categories in the very near future.
